Arcutis Biotherapeutics’ ZORYVE® (roflumilast), a topical treatment for plaque psoriasis, has been awarded the National Psoriasis Foundation’s (NPF) Seal of Recognition. This marks the first time an FDA-approved prescription drug has received this distinction, highlighting ZORYVE’s non-irritating and safe profile for psoriasis patients.
The NPF Seal of Recognition program, launched in 2012, aims to help individuals with psoriasis and psoriatic arthritis identify products that are safe and non-irritating for their skin and joints. The expansion of this program to include FDA-approved prescription drugs underscores the foundation’s commitment to providing a comprehensive range of treatment options for those affected by psoriatic diseases.
ZORYVE, available in both cream and foam formulations, has demonstrated significant efficacy in clearing psoriasis plaques and reducing itchiness across various body areas, including hard-to-treat regions like the scalp and intertriginous areas. The foam formulation, in particular, is uniquely designed for use on hair-bearing and non-hair-bearing skin, offering versatility and convenience for patients.
In clinical trials, such as the phase 3 ARRECTOR study, ZORYVE showed remarkable results, with 66.4% of individuals achieving scalp clearance and 45.5% achieving body clearance at week 8. Additionally, improvements in itchiness were observed as early as 24 hours after the first application.
Leah M. Howard, JD, President and CEO of the NPF, emphasized the importance of this recognition:”It is great for our community to have multiple formulations that are suitable for sensitive and hard-to-treat areas. This reflects real progress in addressing the daily needs of people with psoriasis”.
Frank Watanabe, President and CEO of Arcutis, expressed his gratitude for the recognition:”It is a tremendous honor that ZORYVE is the first FDA-approved product to receive the NPF Seal of Recognition. This recognition reinforces our commitment to developing innovative therapies that meet the real-world needs of people with chronic inflammatory skin diseases”.
With this prestigious recognition, ZORYVE continues to solidify its position as a leading treatment option for plaque psoriasis, offering patients a safe, effective, and convenient alternative to traditional therapies.
Related topics：
